Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin

P M Pil1, S J Lippard

  • 1Department of Chemistry, Massachusetts Institute of Technology, Cambridge 02139.

Science (New York, N.Y.)
|April 10, 1992
PubMed

Insights

High-mobility group protein 1 (HMG1) specifically binds to DNA damaged by the anticancer drug cisplatin. This interaction with cisplatin-induced DNA lesions may explain tumor-specific effects and aid in new drug design.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Development

Background:

  • Cisplatin is an anticancer drug that functions by covalently binding to DNA.
  • Understanding how DNA damage from cisplatin leads to tumor-specific cell death is crucial.
  • Cellular proteins interacting with these DNA lesions are key to this understanding.

Purpose of the Study:

  • To investigate the interaction between cisplatin-induced DNA damage and cellular proteins.
  • To identify specific proteins that recognize and bind to DNA modified by cisplatin.
  • To elucidate the role of such interactions in the mechanism of action of cisplatin.

Main Methods:

  • Utilized recombinant rat high-mobility group protein 1 (HMG1).
  • Assessed the binding affinity of HMG1 to DNA containing specific cisplatin-induced intrastrand cross-links (d(GpG) and d(ApG)).
  • Compared binding to DNA modified by active cisplatin versus inactive platinum analogs.

Main Results:

  • Recombinant rat HMG1 demonstrated specific binding to DNA with cisplatin d(GpG) or d(ApG) intrastrand cross-links.
  • The dissociation constant for HMG1 binding to these lesions was measured at 3.7 +/- 2.0 x 10(-7) M.
  • HMG1 did not bind to DNA modified by therapeutically inactive platinum analogs.

Conclusions:

  • HMG1 specifically recognizes and binds to DNA structures altered by cisplatin.
  • The specific binding of HMG1 to cisplatin-damaged DNA suggests a role in mediating the drug's effects.
  • These findings provide insights into the mechanism of cisplatin cytotoxicity and can inform the design of novel antitumor agents.

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...